KBC Group’s Takeda Pharmaceutical TAK Stock Holding History

KBC Group’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-512	Closed	-$10K	–	1435
2019 Q4	$10K	Buy	+512	New	+$9.79K	﹤0.01%	1478

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KBC Group's TAK Position: Q1 2020 in Review

KBC Group sold out of Takeda Pharmaceutical (TAK) in Q1 2020, closing a stake of 512 shares — an estimated $10K sold.

KBC Group first reported a position in TAK in Q4 2019 and held it in 1 quarter. The position peaked at $10K in Q4 2019. 313 funds tracked by Wall St. Rank hold TAK as of Q1 2020.

KBC Group reported no remaining Takeda Pharmaceutical position as of Q1 2020 after selling out during the quarter.
KBC Group sold 512 Takeda Pharmaceutical shares in Q1 2020, an estimated $10K.
KBC Group first reported a position in Takeda Pharmaceutical in Q4 2019 and held it in 1 quarter.
KBC Group's Takeda Pharmaceutical position peaked at $10K in Q4 2019.
313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2020.

Based on KBC Group's 13F filing for Q1 2020, filed 4 May 2020.